Welcome to our dedicated page for Clarivate Plc news (Ticker: CLVT), a resource for investors and traders seeking the latest updates and insights on Clarivate Plc stock.
Clarivate Plc (NYSE: CLVT) delivers transformative intelligence through market-leading platforms like Web of Science™ and Cortellis™, powering innovation across academia, intellectual property, and life sciences. This news hub provides investors and professionals with direct access to official announcements shaping global research and commercialization efforts.
Track critical updates including quarterly earnings disclosures, strategic partnerships, product launches, and regulatory filings. Our curated feed ensures timely access to press releases about AI-driven analytics advancements, IP portfolio developments, and expansions in pharmaceutical intelligence solutions.
Key content categories include financial performance reports, acquisition announcements, leadership updates, and innovations in real-world data applications. Bookmark this page to monitor Clarivate's progress in converting transactional revenues to high-margin subscriptions while maintaining its position as a critical enabler of R&D workflows.
Clarivate Plc (NYSE: CLVT) reported strong results for Q1 2021, with revenues of $428.4 million, up 78% year-over-year. Adjusted revenues also increased by 78% to $431.5 million. Organic revenues rose 7%, driven by a 6% increase in subscription revenues and a 10% rise in transactional revenues. However, the company faced a GAAP loss from operations of $34.2 million, up 21%. Adjusted EBITDA surged 111% to $164.8 million. Cash from operations was $174 million, significantly higher than the previous year. The company updated its 2021 outlook to forecast 6% to 8% organic growth.
Clarivate Plc (NYSE: CLVT) announced enhancements to its Cortellis Deals Intelligence, introducing new deal trend visualizations and predictive analytics powered by artificial intelligence. These tools aim to streamline the assessment of potential net present value (NPV) for in-licensing candidates in drug development. The integration of real-time data allows users to make informed decisions and better estimate deal sizes. Notably, biopharma deal-making reached record levels in 2020, with nearly $200 billion in transactions.
Clarivate Plc (NYSE: CLVT) has appointed Julie Wilson as the new Chief People Officer, succeeding Andrea Degutis, who retires after four years. This leadership transition occurs during a period of significant growth and transformation for the company. CEO Jerre Stead acknowledged Degutis's vital contributions, especially during the pandemic. Wilson, formerly at Cerner Corporation, brings extensive experience in talent management and a commitment to a high-performance culture. Clarivate aims to enhance employee engagement and profitability while positioning itself as one of the world's best workplaces.
Clarivate Plc (NYSE: CLVT) has released a report highlighting the significant growth of research output in the MENAT region, which has increased from 2% to 8% of global research over the last 40 years. The report identifies Egypt as a key player with 60% international collaboration, while Iran has surpassed other countries in the region to become the largest research producer. Despite high global collaboration, regional collaboration remains low. The study emphasizes the potential for enhanced local collaboration to improve research quality and international competitiveness.
Clarivate Plc (NYSE: CLVT) announced that Jerre Stead, Executive Chairman and CEO, and Richard Hanks, CFO, will present at the BofA Securities 2021 Information Services Conference on March 18, 2021, at 3:35 PM Eastern Time. A live webcast of the presentation will be accessible on the Investor Relations section of Clarivate's website, with a replay available for 30 days post-event. Clarivate aims to accelerate innovation by providing actionable information and insights to help clients navigate complex challenges.
Clarivate Plc (NYSE:CLVT) released its annual 'Drugs to Watch' list, spotlighting potential blockbuster drugs that could exceed $1 billion in sales by 2025. Highlighted drugs include Aducanumab for Alzheimer's, which could revolutionize treatment; Bimekizumab for psoriasis, offering improved efficacy; Relugolix, an oral treatment for prostate cancer; and Vericiguat for heart failure. The report reflects the accelerated pace of biopharma innovation, driven by insights from COVID-19 developments, faster trials, and increased investment in research and development.
Clarivate Plc (NYSE: CLVT) has launched the Web of Science™ Author Impact Beamplots, an innovative tool that visualizes a researcher's publication and citation impact comprehensively. Unlike traditional metrics, beamplots provide a normalized citation count, offering deeper insights into researchers' performance over time. This tool aims to facilitate responsible research evaluation by emphasizing contextual factors such as collaboration and research type. Experts highlight that this method combines quantitative and qualitative indicators for a fairer assessment of researcher contributions.
Clarivate Plc (NYSE: CLVT) announced its participation in the Morgan Stanley Technology, Media and Telecom Conference on March 4, 2021, at 9:30 AM Eastern Time. The presentation will be led by Jerre Stead, Executive Chairman and CEO, alongside Richard Hanks, CFO. A live webcast will be accessible on the Investor Relations section of the Clarivate website, with a replay available for 30 days following the event. Clarivate focuses on providing trusted information and insights to enhance innovation across various sectors.
Clarivate Plc (NYSE: CLVT) reported strong financial results for Q4 and the full year 2020. Q4 revenues reached $456 million, up 79%, while adjusted revenues increased to $471 million, up 85%. Adjusted net income surged 224% to $136 million, with adjusted EBITDA rising 137% to $200 million. Full-year revenues climbed to $1.254 billion, a 29% increase, but net loss improved by 50% to $106 million. The company experienced significant operational enhancements and reaffirmed its 2021 outlook, reflecting confidence in growth from recent acquisitions and strategic objectives.
FAQ
What is the current stock price of Clarivate Plc (CLVT)?
What is the market cap of Clarivate Plc (CLVT)?
